TGTX Form 4: Director Yann Echelard stock sale and holdings

Rhea-AI Filing Summary

TG Therapeutics director reports stock sale to cover taxes

A director of TG Therapeutics, Inc. (TGTX), Yann Echelard, reported a sale of company common stock. On 11/24/2025, 5,000 shares of TG Therapeutics common stock were sold at a price of $32.57 per share, as shown in Table I of the filing. The explanation states that these shares were sold by the company’s restricted stock administrator to satisfy Mr. Echelard’s income tax obligations.

After this transaction, Mr. Echelard beneficially owned 223,816 shares of TG Therapeutics common stock in direct form, which includes shares of restricted common stock that vest over various time periods.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Echelard Yann

(Last) (First) (Middle)

3020 CARRINGTON MILL BLVD, SUITE 475

(Street)

MORRISVILLE NC 27560

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
TG THERAPEUTICS, INC. [ TGTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/24/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/24/2025		S		5,000(1)	D	$32.57	223,816(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares were sold by the Company's restricted stock administrator in order to satisfy Mr. Echelard's income tax obligations.

2. Includes shares of restricted Common Stock, which vest over various time periods.

	/s/ Yann Echelard	11/25/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did TG Therapeutics (TGTX) report in this Form 4?

The Form 4 reports that director Yann Echelard had 5,000 shares of TG Therapeutics common stock sold on 11/24/2025 at $32.57 per share.

Why were TG Therapeutics (TGTX) shares sold in this insider filing?

The explanation states that the 5,000 shares were sold by the company’s restricted stock administrator to satisfy Mr. Echelard’s income tax obligations.

How many TG Therapeutics (TGTX) shares does the reporting person own after the sale?

Following the reported transaction, Yann Echelard beneficially owned 223,816 shares of TG Therapeutics common stock in direct ownership.

What is the relationship of the reporting person to TG Therapeutics (TGTX)?

The reporting person, Yann Echelard, is identified as a director of TG Therapeutics, Inc. on the Form 4.

Does the Form 4 mention restricted stock for TG Therapeutics (TGTX)?

Yes. The footnotes state that the post-transaction holdings of 223,816 shares include restricted common stock that vests over various time periods.

On what date was the earliest transaction in this TG Therapeutics (TGTX) Form 4?

The earliest transaction date reported on the Form 4 is 11/24/2025.